A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: An elusive phenotype and a difficult diagnosis

Summary

Mutations in the A1 domain of von Willebrand factor (VWF) may be associated with gain of function in theVWF-platelet GPIb interaction and consumption of largeVWF multimers, as seen in type 2B von Willebrand disease (VWD). We report a new VWF abnormality associated with greater VWF-GPIb interaction in the presence of all VWF multimers. The index case is a woman with a lifelong history of bleeding, found hyperresponsive to ristocetin with spontaneous platelet aggregation (SPA). She had normal factor VIII,VWF:Ag,VWF:RCo and VWF:CB levels, normal VWF:RCo/VWF:Ag and VWF:CB/VWF:Ag ratios, and a full panel of plasma and platelet VWF multimers. A missense mutation (4115T>G) was found in exon 28 of theVWF gene, which replaced a isoleucine with a serine at position 1372 of pre-pro-VWF (I1372S) at heterozygous level. Recombinant VWF carrying the I1372S mutation and showing a normal VWF multimer organisation was capable of inducing SPA on normal plateletrich plasma (unlike wild-type VWF), as well as a hyper-response to ristocetin in the same platelets (0.6 mg/ml ristocetin vs. 1.2 of wild-type VWF). The new I1372S VWF mutation, characterised by SPA and hyper-responsiveness to ristocetin thus has some of the features of type 2B VWD, but not the lack of large VWF multimers, so we defined this variant as type 2B-likeVWD. Why I1372SVWF is associated with bleeding symptoms, despite normalVWF levels and multimer organisation,remains to be seen.

Keywords

von Willebrand factor - von Willebrand disease - type 2B VWD - VWF mutations - spontaneous platelet aggregation

• References

• 1 Ruggeri ZM, Zimmerman TS. Von Willebrand factor and von Willebrand disease. Blood 1987; 70: 895-904.
• 2 Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005; 3: 775-777.
• 3 Sadler EJ. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-525.
• 4 Sadler JE. Biochemistry and genetics of von Willebrand factor. Ann Rev Biochem 1998; 67: 395-424.
• 5 Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 774-782.
• 6 Ruggeri ZM, Pareti FI, Mannucci PM. et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med 1980; 302: 1047-1051.
• 7 Holmberg L, Nilsson IM, Borge L. et al. Platelet aggregation induced by 1-desamino-8-D arginine vasopressin (DDAVP) in type 2B von Willebrand disease. N Engl J Med 1983; 309: 816-821.
• 8 Gralnick HR, Williams SB, Morisato DK. Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets. Blood 1981; 58: 387-392.
• 9 Casonato A, Steffan A, Pontara E. et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost 1999; 81: 224-228.
• 10 Casonato A, De Marco L, Mazzuccato M. et al. A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand factor platelet interaction and the presence of all von Willebrand factor multimers in plasma. Blood 1989; 74: 2028-2033.
• 11 Weiss H, Sussman I. A new von Willebrand variant (type I New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood 1986; 68: 149-156.
• 12 Holmberg L, Berntorp E, Donner M. et al. Von Willebrand disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Blood 1986; 68: 668-672.
• 13 Federici AB, Mannucci PM, Stabile F. et al. A type 2b von Willebrand disease mutation (Ile546Val) associated with an unusual phenotype. Thromb Haemost 1997; 78: 1132-1137.
• 14 Baronciani L, Federici AB, Beretta M. et al. Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost 2005; 3: 2689-2694.
• 15 Casonato A, Pontara E, Bertomoro A. et al. Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends on the lack of large multimers. J Lab Clin Med 1997; 129: 251-259.
• 16 Gallinaro L, Sartorello F, Pontara E. et al. Combined partial exon skipping and cryptic splice site activation as a new molecular mechanisms for recessive type 1 von Willebrand disease. Thromb Haemost 2006; 96: 711-716.
• 17 Mancuso DJ, Tuley EA, Westfield LA. et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-19527.
• 18 Goodeve AC, Eikenboom JCJ, Ginsburg D. et al. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. Thromb Haemost 2001; 85: 929-931.
• 19 Casonato A, De Marco L, Gallinaro L. et al. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain. Thromb Haemost 2007; 97: 527-533.
• 20 Hillery CA, Mancuso DJ, Sadler EJ. et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91: 1572-1581.
• 21 Randi AM, Jorieux S, Tuley EA. et al. Von Willebrand factor Arg(578)→Gln: a type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not collagen or heparin. J Biol Chem 1992; 267: 21187-21192.
• 22 Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-297.
• 23 Francesconi MA, Deana R, Girolami A. et al. Platelet aggregation induced by plasma from type IIB von Willebrand’s disease patients is associated with an increase in cytosolic Ca2+ concentration. Thromb Haemost 1993; 70: 697-701.
• 24 Randi AM, Rabinowitz I, Mancuso DJ. et al. Molecular basis of von Willebrand disease type-IIB-candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein-Ib binding sequences. J Clin Invest 1991; 87: 1220-1226.
• 25 Schneppenheim R, Budde U. Phenotypic and genetic diagnosis of von Willebrand disease: a 2004 update. Semin Hamatol 2005; 42: 15-28.
• 26 Holmberg L, Dent JA, Schneppenheim R. et al. Von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. J Clin Invest 1993; 91: 2169-2177.
• 27 Rayes J, Hommais A, Legendre P. et al. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J Thromb Haemost 2006; 5: 321-328.
• 28 Zheng XL, Chung D, Takayama TK. et al. Structure of von Willebrand factor-cleaving protease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
• 29 Dent JA, Berkowitz SD, Ware J. et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc. Natl Acad Sci USA 1990; 87: 6306-6310.
• 30 Nishio K, Anderson PJ, Zheng XL. et al. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA 2004; 101: 10578-10583.
• 31 Nurden P, Chretien F, Poujol C. et al. Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease. Br J Haematol 2000; 110: 704-714.
• 32 Casonato A, Pontara E, Bertomoro A. et al. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?. Br J Haematol 2001; 112: 578-583.